[1] Senzolo M, Garcia-Tsao G, Garcia-Pagan JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol,2021,75(2):442-453.
[2] Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020,Shanghai). J Dig Dis,2021,22(4):176-186.
[3] Faccia M, Ainora ME, Ponziani FR, et al. Portal vein thrombosis in cirrhosis:why a well-known complication is still matter of debate. World J Gastroenterol,2019,25(31):4437.
[4] Serper M, Weinberg EM, Cohen JB, et al. Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology,2021,73(1):219-232.
[5] Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol,2021,75(6):1367-1376.
[6] Maruyama H, Okugawa H, Takahashi M, et al. De novoportal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol,2013,108(4):568-574.
[7] Sacchetti S, Puricelli C, Mennuni M, et al.Research into new molecular mechanisms in thrombotic diseases paves the way for innova-tive therapeutic approaches. Int J Mol Sci,2024,25(5):2523.
[8] Brusilovskaya K, Hofer BS, Simbrunner B, et al. Platelet function decreases with increasing severity of liver cirrhosis and portal hypertension-a prospective study. Thromb Haemost,2023,123(12):1140-1150.
[9] Zifkos K, Dubois C, Schäfer K. Extracellular vesicles and thrombosis: update on the clinical and experimental evidence. Int J Mol Sci,2021,22(17):9317.
[10] Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin‐rich thrombus. Hepatology,2022,75(4):898-911.
[11] 崔冶齐,张世斌.肝硬化门静脉血栓分类及形成机制研究进展.实用肝脏病杂志,2025,28(2):161-164.
[12] Kang H, Kim S, Park S, et al. Small leucine zipper protein negatively regulates liver fibrosis by suppressing the expression of plasminogen activator inhibitor-1. Exp Cell Res,2024,442(2):114258.
[13] Scheiner B, Balcar L, Nussbaumer RJ, et al. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. J Hepatol,2022,76(5):1090-1099.
[14] Zhang Y, Liang X, Bao X, et al. Toll-like receptor 4 (TLR4) inhibitors: current research and prospective. Eur J Med Chem,2022,235:114291.
[15] Li W, Chang N, Li L. Heterogeneity and function of Kupffer cells in liver injury. Front Immunol,2022,13:940867.
[16] 靳珂珂,丁惠国.肝硬化门静脉血栓形成风险监测及抗凝管理.实用肝脏病杂志,2024,27(1):3-6.
[17] Hassnine AA, Elsayed AM. COVID‐19 in cirrhotic patients: is portal vein thrombosis a potential complication? Can J Gastroenterol Hepatol,2022, 2022(1):5900468.
[18] Nery F, Carneiro P, Correia S, et al. Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study. Eur J Gastroenterol Hepatol,2021,33(1S):e108-e113.
[19] Xing Y, Tian Z, jiang Y, et al.A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis. Ann Med,2022,54(1):302-309.
[20] 李玲,陆申新,崔春晓,等.591例肝硬化患者门静脉血栓形成的危险因素分析.复旦学报(医学版),2017,44(03):288-293.
[21] Gîrleanu I, Trifan A, Cojocriu C, et al. The risk of thrombotic events in patients with liver cirrhosis. Rev Med Chir Soc Med Nat Lasi,2012,116(4):991-996.
[22] Ak C, Adali G, Sayar S, et al. Portal vein thrombosis risk factors in liver transplant candidates. Hepatol Forum,2022,3(3):88.
[23] Gaballa D, Bezinover D, Kadry Z, et al. Development of a model to predict portal vein thrombosis in liver transplant candidates: the portal vein thrombosis risk index. Liver Transpl,2019,25(12):1747-1755.
[24] Qi X, Han G, Ye C, et al. Splenectomy causes 10-fold increased risk of portal venous system thrombosis in liver cirrhosis patients.Med Sci Monit,2016,22:2528.
[25] Xu X, Guo X, De Stefano V, et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int,2019,13:468-481.
[26] Qi X, Guo X, Yoshida EM, et al. Transient portal vein thrombosis in liver cirrhosis. BMC Ded,2018,16:1-11.
[27] Giri S, Singh A, Kolhe K, et al. Natural history of portal vein thrombosis in cirrhosis:a systematic review with Meta‐analysis.J Gastroenterol Hepatol,2023,38(10):1710-1717.
[28] Yokoyama S, Ishizu Y, Honda T, et al. Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis. Hepatol Res,2022,52(2):199-209.
[29] Xu S, Guo X, Xu X, et al. Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis.Eur J Gastroenterol Hepatol,2021,33(1S):e423-e430.
[30] Nicoară-Farcău O, Soy G, Magaz M, et al. New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis. Semin Thromb Hemost,2020,46(06):673-681.
[31] Luca A, Caruso S, Milazzo M, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology,2012,265(1):124-132.
[32] Yao C, Zhao M, Ibrahim B, et al. Anticoagulation for the treatment of portal vein thrombosis in cirrhosis: a systematic review and meta-analysis of comparative studies. J Clin Exp Hepatol,2023,13(3):404-413.
[33] Scheiner B, Stammet PR, Pokorny S, et al.Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function.Wien Klin Wochenschr,2018,130(13-14):446-455.
[34] Guerrero A, Del Campo L, Piscaglia F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis:the importal competing-risk Meta-analysis. J Hepatol,2023,79(1):69-78.
[35] Lisman T.Treatment of portal vein thrombosis in cirrhosis with anticoagulation—more than meets the eye? Hepatobiliary Surg Nutr,2024,13(2):321.
[36] Senzolo M, Garcia-Pagan JC. A major research gap: the use of anticoagulants in cirrhosis. J Hepatol,2023,79(6):1566-1570.
[37] Noronha Ferreira C, Reis D, Cortez-Pinto H, et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis. Dig Dis Sci,2019,64:2671-2683. |
